ClinicalTrials.gg
RecruitingNCT07328217Updated Feb 11, 2026

A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of GW5282 and GW5282 in Advanced Solid Tumors, sponsored by Dizal Pharmaceuticals. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Dizal Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
203
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 1/2, open-label, multicenter study assessing the safety, tolerability, pharmacokinetics and efficacy of GW5282 in participants with locally advanced or metastatic solid tumors. This study comprised of a dose escalation phase to determine the MTD and the RP2D and a dose expansion phase to further explore the safety, PK and efficacy of GW5282.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Dizal Pharmaceuticals is the lead sponsor of 39 studies on the registry; 15 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All participants must provide a signed, dated written (ICF) prior to any study-specific procedures, sampling, and analysis.
  2. Male and female participants must be ≥18 years of age at the time of signing the ICF.
  3. performance status of 0-1.
  4. or cytologically confirmed locally advanced or solid tumors who has failed standard of cares (SoCs).
  5. ≥3 months.
  6. At least one according to 1.1.
  7. Tumor tissue sample requirements: sections of formalin-fixed paraffin-embedded (FFPE) tissue from freshly obtained sample or archived tumor sample.
  8. Adequate organ and marrow function.
  9. Participants should be able to comply with the requirements of this study for medication use and follow-up.
  10. If the female partner of a male participant has a potential for pregnancy, he must agree to use (such as condoms) and refrain from donating sperm during the treatment period and for at least 6 months after the last dose of study treatment.
  11. Female participants should use adequate contraception during the treatment period and for at least 3 months after the last dose of study treatment. Female participants with potential pregnancy should have a negative pregnancy test prior to the first administration of drug. Female participants may also be enrolled if they meet one of the following criteria:

    • women: older than 50 years and more than 12 months postmenopausal after discontinuation of all exogenous hormone therapy. Women under 50 years of age, more than 12 months postmenopausal after discontinuation of all exogenous hormone therapy, and with luteinizing hormone and follicle-stimulating hormone levels at postmenopausal levels.
    • History of irreversible hysterectomy, bilateral oophorectomy, or bilateral salpingectomy (excluding tubal ligation)."

Exclusion criteria

Exclusion Criteria:

  1. Any unresolved > grade 1 (according to version 5.0) adverse event (excluding alopecia, anemia, neutropenia, and thrombocytopenia) prior to the first administration of drug.
  2. Any known active central nervous system and/or carcinomatous meningitis and/or spinal cord compression.
  3. Having any of the following treatment history:

    • previously treated with GW5282 or other EZH pathway inhibitors.
    • previously received any cytotoxic chemotherapy, investigational drug, or other anticancer drug (excluding macromolecular drugs) or clinical trial within 7 days or 5 half-lives (whichever is longer) prior to the first administration of the investigational drug.
    • previously received any macromolecular drug (such as immunotherapy, monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates) within 28 days prior to the first administration of the investigational drug.
    • Underwent major surgery (excluding vascular access surgery) or suffered severe trauma within 4 weeks prior to the first administration of the investigational drug.
    • Received limited field of radiation to alleviate symptoms within 7 days prior to the first administration of the investigational drug, or received more than 30% or extensive field of radiation to the bone marrow within 28 days prior to the first administration of the investigational drug.
    • Received or viral vector vaccine within 4 weeks prior to the first administration of the investigational drug."
  4. Active infectious diseases.
  5. History of stroke or intracranial hemorrhage within 6 months prior to the first administration of the investigational drug.
  6. History of interstitial lung disease (ILD), radiation pneumonitis requiring therapy, or any clinically active interstitial lung disease, or immunotherapy-related pneumonitis.
  7. Uncontrolled systemic disease including uncontrolled hypertension and active bleeding after investigator's assessment.
  8. Judgment by the investigator that the participant is unlikely to comply with the study procedures, restrictions, and requirements.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
203 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Phase

    Escalating doses of GW5282 administered orally

    Drug: GW5282

  • Experimental
    Dose Expansion phase

    The recommended dose(s) for expansion (RDFE) for GW5282 from dose escalation phase will be evaluated in selected tumors.

    Drug: GW5282

Interventions

  • DrugGW5282

    Single dose period (only for dose escalation phase): administered one single dose at assigned dose level orally. Repeated does period (for dose escalation phase and dose expansion phase): administered at assigned dose levels and schedules twice daily (BID) orally in 21-day cycles continuously.

  • DrugGW5282

    RDFE will be determined by dose escalation phase.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLTs) (Dose Escalation only)

    Time frame: Up to 21 days

  2. Number of participants with Adverse Events (AEs)

    Time frame: Approximately 24 months from first participant enrolled

  3. Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Approximately 24 months from first participant enrolled

  4. Overall Response Rate (ORR)

    ORR is defined as the percentage of subjects with Best Response of Complete Response (CR) or Partial Response (PR) as determined by the investigator

    Time frame: Approximately 24 months from first participant enrolled

Secondary outcomes

  1. Cmax; Maximum Plasma Concentration of GW5282

    Time frame: Single dose period (only for dose escalation phase): 0 (predose) up to 72 hours post-dose

  2. AUC; Area Under the Plasma Concentration-time Curve of GW5282

    Time frame: Single dose period (only for dose escalation phase): 0 (predose) up to 72 hours post-dose

  3. Tmax; Time to Reach Maximum Plasma Concentration (Cmax) of GW5282

    Time frame: Single dose period (only for dose escalation phase): 0 (predose) up to 72 hours post-dose

  4. Css,max; Maximum Steady State Plasma Concentration of GW5282

    Time frame: Cycle 1 Day 15: 0 (predose) up to 12 hours post-dose

  5. AUCss; Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady State of GW5282

    Time frame: Cycle 1 Day 15: 0 (predose) up to 12 hours post-dose

  6. Tss,max; Time to Reach Maximum Plasma Concentration (Cmax) at Steady State of GW5282

    Time frame: Cycle 1 Day 15: 0 (predose) up to 12 hours post-dose

  7. Duration of response (DOR)

    DOR is defined as the time from the date of first documented response until date of documented progression, for subjects who achieve CR or PR

    Time frame: Approximately 24 months from first participant enrolled

  8. Disease Control Rate (DCR)

    DCR is defined as the percentage of subjects who have a best overall response of CR or PR or SD as determined by the investigator

    Time frame: Approximately 24 months from first participant enrolled

  9. Progression-free survival (PFS)

    PFS is defined as the time from date of first dose until progression as assessed by the investigator or death due to any cause

    Time frame: Approximately 24 months from first participant enrolled

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2025
First posted
Jan 9, 2026
StartActual
Jan 29, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07328217
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Jan 29, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Feb 11, 2026

Study contacts

Sherry Hu
Contact
sherry.hu@dizalpharma.com
+86 02161568345
Mengzhao Wang
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion